医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

BioCision to Develop Controlled-Rate Cell Freezing Systems for Cook Regentec Cell Therapy Vials

2015年07月28日 PM09:00
このエントリーをはてなブックマークに追加


 

SAN RAFAEL, Calif.

BioCision, LLC today announced that they have entered into an exclusive partnership with Cook Regentec to develop two custom CoolCell® controlled-rate cell freezing systems for Cook’s closed-system cell therapy CellSeal® vials.

Cook selected BioCision’s proprietary CoolCell technology for its effectiveness in standardizing the freezing of cells and cellular therapies such as stem cells and tissue samples that can be used in a wide range of applications from diabetes research to organ transplants. The ease of implementation and use of CoolCell freezing systems, especially as compared to expensive controlled-rate freezers, will provide Cook’s CellSeal vial customers a cost-effective, reliable solution for controlled -1 degree Celsius per minute cell freezing, the rate believed to be optimal to ensuring cells remain intact and experience minimal negative effects during the freezing process.

“Our CoolCell technology platform is ideal for customization into emerging formats, such as the CellSeal closed-system vial,” said Dr. Rolf O. Ehrhardt, CEO of BioCision. “This partnership with Cook Regentec, a leader in the field of cell therapy, will enable users of these vials to standardize the cryopreservation of their cell therapy products. This is an important step forward for the industry and, most importantly, for the patients who rely on precise handling of these sensitive materials.”

This agreement encompasses the development of two customized cell freezing CoolCell systems for Cook’s CellSeal vials, as well as the adaptation of other BioCision technology platforms to this format, and is the latest in a series of customized products BioCision has developed for the cell therapy industry.

ABOUT BIOCISION

BioCision is a life science research and development company that standardizes processes throughout the healthcare industry. BioCision products enable researchers, clinicians and manufacturers to protect temperature sensitive therapeutics, biological samples, and biomaterials. By addressing temperature stability, BioCision strives to improve the success of therapeutic discovery and development and enable effective care delivery.

For more information visit www.biocision.com, or visit the BioCision blog for news and expert insight at blog.biocision.com.

CoolCell® is a registered trademark of BioCision, LLC, and CellSeal® is a registered trademark of Cook General Biotechnology, LLC.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150728005596/en/

CONTACT

BioCision
Marla Kertzman, 209-852-9027
mkertzman@biocision.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表